Claims:

1. *N*-{(*R*)-1-[8-Chloro-2-(1-oxypyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}-pyrido[3,2-*d*]pyrimidin-4-ylamine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).

2. The use of *N*-{(*R*)-1-[8-chloro-2-(1-oxypyridin-3-yl)quinolin-3-yl]-2,2,2-trifluoroethyl}pyrido[3,2-*d*]pyrimidin-4-ylamine, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and/or prevention of activated phosphoinositide 3-kinase delta syndrome (APDS).

3. The compound for the use according to claim 1, or the use according to claim 2, wherein the APDS comprises APDS1 and APDS2.

4. The compound for the use according to claim 1, or the use according to claim 2, wherein the APDS is APDS1.

5. The compound for the use according to claim 1, or the use according to claim 2, wherein the APDS is APDS2.